Immunicum and the University Medical Center Groningen Receive a Grant from Health~Holland to Broaden Cancer Relapse Vaccine Development for Ovarian Cancer
Press Release
8 September 2021
Immunicumandthe University Medical Center GroningenReceive a Grant from Health~Hollandto Broaden Cancer Relapse Vaccine Development for Ovarian Cancer
Immunicum AB (publ; IMMU.ST) announced today that it has initiated a new research collaboration with theUniversity Medical Center Groningen (UMCG), toexplorenovel treatment options for ovarian cancer based on the combination of Immunicum’s cell-based cancer vaccine platform with immune checkpoint inhibitors (CPI).The project is supported by a grant fromHealth~Holland, Top Sector Life Sciences & Health (LSH).
The 3-year preclinical research project will be conducted together with the laboratory of Dr. Marco de Bruyn and Prof. Dr. Hans W. Nijman at UMCG, Department of Obstetrics & Gynecology. Under the terms of the agreement, Immunicum will combine its expertise in allogeneic dendritic cell and T cell biology with UMCG’s research experience in ovarian cancer and targeted genomic modulation, in order to elucidate potential synergies between Immunicum’s lead cancer relapse vaccine candidate DCP-001, and CPIs in ovarian cancer.
“This collaboration extends our existingrelationship with UMCG and supports the development of cancer relapse vaccination as a novel approach for the treatment of ovarian cancer. It also exemplifies Immunicum’s commitment to continue to invest in its academicpartnerships,” said Alex Karlsson-Parra, Chief ScientificOfficer at Immunicum.
Immunicum has an ongoing clinical collaboration with UMCG for the ALISON study, a single-center, open-label Phase I study evaluating safety and efficacy of DCP-001 in High-Grade Serous Ovarian Cancer (HGSOC) patients. Immunicum and UMCG had previously completed a preclinical research study demonstrating the stimulation of immune responses against ovarian cancer cells by DCP-001. The data from this study will be presented at the upcoming European Society for Gynaecological Oncology conference, held October 23-25.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
Telephone: +31 713 322 627
E-mail: ir@immunicum.com
INVESTOR RELATIONS
Kristina Windrup Olander
Spikinc AB
Telephone: +46 72 545 34 74
E-mail: ir@immunicum.com
MEDIA RELATIONS
Sophia Hergenhan & Jacob Verghese
Trophic Communications
Telephone: +49 160 90816161
E-mail: immu@trophic.eu
ABOUT HEALTH~HOLLAND, TOP SECTOR LIFE SCIENCES & HEALTH (LSH)
The Health~Holland, Top Sector LSH grant, known as PPP-Allowance or TKI-toeslag, is awarded to fund multidisciplinary public private partnerships and to stimulate innovative, interdisciplinary research and development by bringing together stakeholders in a shared, consolidated innovation infrastructure. The Top Consortia for Knowledge and Innovation (TKI) grant, which is made available by the Dutch Ministry of Economic Affairs and Climate Policy, can also be used to support new research projects. https://www.health-holland.com/funding-opportunities/tki-match
ABOUT UMCG
The University Medical Center Groningen (UMCG) is the only university hospital in the northern part of the Netherlands, and therefore the final point of referral for many patients. Research at the UMCG is characterized by a combination of fundamental and patient oriented clinical research. The UMCG focuses on healthy ageing in all priority areas: research, clinical care and education. https://www.umcg.nl/EN/corporate/The_University_Medical_Center/Paginas/default.aspx
ABOUT IMMUNICUM AB (PUBL)
Immunicum is leveraging its unparalleled expertise in allogeneic dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
HSBC Continental Europe: Post Stabilisation Notice26.4.2024 09:30:00 CEST | Press release
ASR Nederland N.V. Post Stabilisation Notice PARIS, April 26, 2024 (GLOBE NEWSWIRE) -- HSBC (contact: syndexecution@noexternalmail.hsbc.com) hereby gives notice that no stabilisation was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer:ASR Nederland N.V.Guarantor (if any):naAggregate nominal amount:EUR 500,000,000Description:6.625% due PerpetualNC8.25yrOffer price:100Stabilising Manager:HSBC Continental Europe This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further informat
Konsolidator maintains its financial expectations for 202426.4.2024 09:26:41 CEST | Press release
Company announcement no 8-2024 Søborg, April 26, 2024 Konsolidator maintains its financial expectations for 2024 In Q1 2024, Konsolidator delivered ARR growth of 4% (YoY). The focus has been on establishing our Iberia sales office and preparing and launching the growth initiatives, including the new Microsoft D365 partner channel. Improving churn and increasing direct sales remain top priorities together with the growth initiatives. Konsolidator maintains its financial expectations of DKK 24-28m in ARR in 2024. 2024 is well underway, and Konsolidator has signed 7 new customers. However, Konsolidator has also lost 11 customers during Q1 2024m, thus churn has the utmost attention. Konsolidator expects to see an improvement in churn in the second half of 2024. In Q1 2024, Konsolidator initiated a Customer Success academy, which will be implemented in Q2 2024. Further in March 2024, Konsolidator elected a new board member, Michael Rasmussen. As VP of technical engagement in the SaaS compan
Offentliggørelse af prospekt samt formue og investorer for afdelingen HP Invest Bolig i Investeringsforeningen Wealth Invest26.4.2024 09:00:00 CEST | Press release
Hermed offentliggøres prospekt samt formue og antal investorer for afdelingen HP Invest Bolig, som optages til handel på Nasdaq Copenhagen A/S med første handelsdag 30. april 2024. Afdelingen har en formue på DKK 149.760.924 og 22 navnenoterede investorer. Hvis der måtte være spørgsmål i relation til ovenstående, kan der rettes henvendelse til direktør i Investeringsforvaltningsselskabet SEBinvest A/S, Lise Bøgelund Jensen på telefon 3328 2828. Med venlig hilsen Investeringsforeningen Wealth Invest Attachment 2024 04 26 Prospekt WI HP Invest Bolig_final
Spar Nord indfrier Tier 2 kapital med ISIN koderne DK0030431341 og DK003043207526.4.2024 08:50:00 CEST | pressemeddelelse
Selskabsmeddelelse nr. 29 Det oplyses hermed, at Spar Nord har fået Finanstilsynets tilladelse til at indfri obligationslån med ISIN kode DK0030431341 på DKK 150 mio. og ISIN kode DK0030432075 på DKK 350 mio. begge med status af Tier 2 kapital. Indfrielsen finder sted 29. maj 2024. Spørgsmål i forbindelse med denne meddelelse kan rettes til undertegnede på 96 34 42 36 eller mail rsn@sparnord.dk. Venlig hilsen Rune Brandt Børglum IR-chef Vedhæftet fil Nr. 29 - Spar Nord indfrier Tier 2-kapital - DK
Spar Nord repays Tier 2 capital with ISINs DK0030431341 and DK003043207526.4.2024 08:50:00 CEST | Press release
Company announcement no. 29 It is hereby announced that Spar Nord has received the permission of the Danish Financial Supervisory Authority to repay bond loans (ISIN DK0030431341) for DKK 150 million and (ISIN DK0030431341) for DKK 350 million, currently both classified as Tier 2 capital. The repayment will take place on 29 May 2024. Please direct any questions regarding this release to Rune Brandt Børglum, Head of Investor Relations, on tel. + 45 9634 4236, or by e-mail at rsn@sparnord.dk. Rune Brandt Børglum Head of Investor Relations Attachment No. 29 - Spar Nord repays Tier 2 capital - UK